For example, the Food and Drug Administration (FDA) approved patozumab and TDM-1 in HER2-positive advanced breast cancer patients in 2012 and 2013, respectively (30, 31), Pfizer’s Palbiclib as an initial endocrine therapy scheme in 2015, and the PARP inhibitor Olaparib for treating BRCA1 or BRCA2 gene mutation breast cancer patients (32). The gene discussed is ERBB2; the disease is breast cancer.